Scientific and Ethical Issues in the Use of Placebo and Active Controls in Clinical Trials

Journal of Bone and Mineral Research

Volumn 18, Issue 6, 2003, Pages 1121-1124

  Ellenberg, Susan S ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; PHENOTHIAZINE DERIVATIVE; PLACEBO; QUETIAPINE; RESERPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

CLINICAL RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DEPRESSION; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG RESEARCH; DRUG TOLERABILITY; DRUG USE; EXTRAPYRAMIDAL SYMPTOM; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPOKALEMIA; INFORMED CONSENT; MEDICAL ETHICS; MEDICAL INFORMATION; OUTCOMES RESEARCH; RELIABILITY; SEDATION; SIDE EFFECT;

BIOMEDICAL AND BEHAVIORAL RESEARCH;

BIOETHICS; CONTROLLED CLINICAL TRIALS; HUMAN EXPERIMENTATION; HUMANS; PLACEBOS; REPRODUCIBILITY OF RESULTS;

EID: 0142122890     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2003.18.6.1121     Document Type: Conference Paper

References (26)

1. Temple RT, Ellenberg SS 2000 Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: Ethical and scientific issues. Ann Intern Med 133:455-463.
2. Ellenberg SS, Temple RT 2000 Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: Practical issues and specific cases. Ann Intern Med 133:464-470.
3. Jones B, Jarvis P, Lewis JA, Ebbutt AF 1996 Trials to assess equivalence: The importance of rigorous methods. BMJ 313:36-39.
4. Lewis JA, Jonsson B, Kreutz G, Sampaio C, van Zwieten-Boot B 2002 Placebo-controlled trials and the Declaration of Helsinki. Lancet 359:1337-1340.
5. Lasagna L 1979 Placebos and controlled trials under attack. Eur J Clin Pharmacol 15:373-374.
6. Fleming TR 1987 Treatment evaluation in active control studies. Cancer Treat Rep 71:1061-1065.
7. International Conference on Harmonization 2001 Choice of Control Group in Clinical Trials, Guideline E10. Available online at http://www.ifpma.org/ich5e.html. Accessed on April 7, 2003.
8. Khan A, Warner HA, Brown WA 2000 Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: An analysis of the Food and Drug Administration database. Arch Gen Psychiatry 57:311-317.
9. Baldessarini RJ, Jamison KR 1999 Effects of medical interventions on suicidal behavior. Summary and conclusions. J Clin Psychiatry 60(Suppl 2):117-122.
10. Laughren TP 2001 The scientific and ethical basis for placebo-controlled trials in depression and schizophrenia: An FDA perspective. Eur Psychiatry 16:418-423.
11. LaRosa JC, He J, Vupputuri S 1999 Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials. JAMA 282:2340-2346.
12. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, Bulpitt CJ, deLeeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O'Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A 1994 Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 350:757-764.
13. Bath P 1998 Alteplase not yet proven for acute ischaemic stroke. Lancet 352:1238-1239.
14. Katzen IL, Sila CA, Furlan AJ 2001 Community use of intravenous tissue plasminogen activator for acute stroke: Results of the Brain Matters Stroke Management Survey. Stroke 4:861-865.
15. Henry D, Hill S 1995 Comparing treatments. BMJ 310:1279.
16. Rothman KJ, Michels KB 1994 The continued unethical use of placebo controls. N Engl J Med 331:394-398.
17. Freedman B, Weijer C, Glass KC 1996 Placebo orthodoxy in clinical research I: Empirical and methodological myths. J Law Med Ethics 24:243-251.
18. Freedman B, Weijer C, Glass KC 1996 Placebo orthodoxy in clinical research II: Ethical, legal, and regulatory myths. J Law Med Ethics 24:252-259.
19. Tramer MR, Reynolds DJ, Moore RA, McQuay HU 1998 When placebo controlled trials are essential and equivalence trials are inadequate. BMJ 317:875-880.
20. Emanuel EJ, Miller FG 2001 The ethics of placebo-controlled trials-a middle ground. N Engl J Med 345:915-919.
21. Lurie P, Wolfe SM 1997 Unethical trials of interventions to reduce perinatal transmissions of the human immunodeficiency virus in developing countries. N Eng J Med 337:853-856.
22. Perinatal HIV Intervention Research in Developing Countries Workshop participants 1999 Science, ethics, and the future of research into maternal infant transmission of HIV-1. Lancet 353: 832-835.
23. Varmus H, Satcher D 1997 Ethical complexities of conducting research in developing countries. N Engl J Med 337:1003-1005.
24. Senn S 2001 The misunderstood placebo. Appl Clin Trials 5:1-5.
25. World Medical Association 2001 Declaration of Helsinki (as revised and clarified). Available online at www.wma.net/e/policy/17-c_e.html. Accessed on April 7, 2003.
26. Council for International Organizations of Medical Sciences 2002 International ethical guidelines for biomedical research involving human subjects (as revised). Available online at www.cioms.ch/frame_guidelines_nov_2002.htm. Accessed on April 7, 2003.